BioOutsource Ltd. acquired by Sartorius Stedim Biotech

April 17, 2015 2:29 PM

BioOutsource, a leading provider of contract testing services for the biopharmaceutical industry, has been acquired by Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industries.

BioOutsource provides contract testing services to Global biopharmaceutical clients in order to monitor the safety and quality of biologic drugs and vaccines. This acquisition will develop SSB’s service offering throughout the drug development pathway. The contractual parties agreed not to disclose any further details of the transaction.

Welcoming the acquisition, Gerry MacKay, CEO of BioOutsource said “We are delighted to have found a strong partner with a broad customer base, international reach and a powerful brand. With Sartorius Stedim Biotech we will be able to scale our business to the next level and invest in new adjacent services. As a part of this group, we will have the opportunity to work with more international customers particularly in areas like the United States and Asia where there is significant investment in biosimilar development and manufacturing. We would also like to take this opportunity to thank one of our original shareholders Scottish Investment Bank, the investment arm of Scottish Enterprise, for their continued investment and support over the last 7 years”.

Reinhard Vogt, member of SSB’s Board, commented: “By adding contract testing services, we will be able to support our biopharma clients even better in their drive to fast-track their new drug candidates through the development and clinical test phases and facilitate lot release testing in large scale manufacturing. The highly qualified team at BioOutsource will ideally complement our expertise, and we are looking forward to working with them.”

Source: BioOutsource press release


Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!